Sign In
21 Sep 2009 07:00
ļ»æ
21Ā September 2009
Minster Pharmaceuticals plc
("Minster" or the "Company")
Minster Pharmaceuticals plcĀ (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that Robert Aubrey, an Executive Director,Ā will step downĀ from executive responsibilitiesĀ with effect fromĀ 30 SeptemberĀ 2009Ā to become aĀ Non-executive Director.
Mr Aubrey has served the CompanyĀ in an executive capacity forĀ a total of 8 years. He isĀ stepping down from executive responsibilities following the successful completion of the transfer ofĀ finance and internal control procedures to Karl Keegan, Chief Financial Officer, who was appointed in April 2009.
John Russell,Ā Minster'sĀ Chairman,Ā said:Ā "Bob hasĀ made an impressiveĀ contributionĀ to MinsterĀ during hisĀ eightĀ years as an executive. We are particularlyĀ pleased that heĀ has agreedĀ toĀ continue to serve the Company asĀ aĀ Non-executive Director, through which we can continue to benefit from his wise counsel."
For further information:
Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623 John Russell, Chairman and Interim CEOĀ Karl Keegan, Chief Financial Officer Tel: +44 (0) 20 7936 9921 Buchanan Communications Tel: +44 (0) 20 7466 5000 Mark Court / Catherine BreenĀ Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200 Chris Collins / Richard Potts
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visitĀ www.minsterpharma.com
Follow the stocks
